SAN DIEGO, Calif., - (http://www.financialnewsmedia.com News Alert) - Regen BioPharma, Inc. (OTCBB: RGBP) (OTC: RGBP) announced today the initiation of a collaboration with Dr. Santosh Kesari , Professor and Director of Neuro-oncology at University of California San Diego . The goals of the collaboration is to address questions posed by the FDA regarding Regn BioPharma, Inc.\'s planned Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer and to modify the existing Investigational New Drug application in order to maximize the probability of clinical trial success . The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last one year, with tumor assessment before therapy and at 6 and 12 months.
\"Using the immune system to treat cancer offers great potential in that the immune system destroys tumor cells, but then establishes immunological memory, which constantly patrols the body for rogue cells.\" Said Dr. Kesari, \"Having served as a member of Regen\'s Scientific Advisory Board, I am excited to be involved in this collaboration, in which we aim to help expediently address the questions posed by the FDA and allow for clinical entry of dCellVax.\"
\"As a company we have been fortunate to attract collaborators with established track records of bringing drugs from bench to bedside.\" Said Thomas Ichim, Ph.D, Chief Scientific Officer of Regen BioPharma. \"In addition to being an internationally renowned clinician, having participated in over 50 clinical trials, Dr. Kesari has been the author of over 200 scientific publications and is the inventor on numerous patents and patent applications in the area of oncology and immunology. This combination of academic and clinical success is ideal for the current collaboration in which we are trying to address issues at the intersection between basic science and applied medicine. This collaboration will provide us the benefit of Dr. Kesari\'s years of expertise in oncology drug development and clinical practice.\"
ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) (OTC PINK: RGBP). The Company...
$RGBP News - Cancer Clinical Trials Expert Dr. Santosh Kesari to Assist Regen BioPharma, Inc. in Addressing FDA Questions Regarding Planned dCellVax Immunotherapy Clinical Trial for Breast Cancer
June 10, 2015 at 08:28 AM EDT
